Skip to content
Screener

Ultragenyx Pharmaceutical RARE Liability Related To Sale Of Future Royalties

Liability Related To Sale Of Future Royalties at other companies

Kodiak Sciences Inc logo
Kodiak Sciences IncKOD
$100M0.0%
Geron logo
GeronGERN
$20.69M+18.6%
Geron logo
GeronGERN
$20.69M+18.6%
Arbutus Biopharma Corporation logo
Arbutus Biopharma CorporationABUS
$3.28M-25.7%
Zymeworks logo
ZymeworksZYME
$252.63M—
Zymeworks logo
ZymeworksZYME
$252.63M—

Other financials

Income statement

See full
Revenue$214.0M+28.1%
Operating income-$75.0M+30.6%
Net income-$92.0M+20.0%
EPS (diluted)-$0.90+23.1%

Balance sheet

See full
Cash & equivalents$125.0M-29.0%
Total debt$36.0M-10.8%
Total equity-$291.0M-293%
Total assets$1.3B-3.2%

Cash flow

See full
Operating cash flow-$97.0M+11.0%
CapEx$1.0M-66.7%
Free cash flow-$98.0M+12.5%

Valuation

See full
Market cap$2.46B-9.2%
P/S3.4×-1.0×

Profitability

See full
Gross margin97.2%—
Operating margin-73.6%-7.3pp
Net margin-81.7%-4.9pp
FCF margin-68.2%-1.7pp

Returns & leverage

See full
Return on equity-325.6%+36.9pp
Debt / equity3.7×—
Current ratio1.7×-0.7×

Where this comes from

Reported directly by Ultragenyx Pharmaceutical in its filing.

Tagged under the XBRL concept rare:LiabilityRelatedToSaleOfFutureRoyalties.

The source filing: Ultragenyx Pharmaceutical’s 10-Q, filed August 5, 2026.

Filed
Aug 4, 2026, 8:00 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-333233
Line itemJune 30, 2026December 31, 2025
Other liabilities1519
Total current liabilities351384
Deferred tax liabilities3030
Liabilities for sales of future royalties1,1261,147
Other liabilities4144
Total liabilities1,5481,605
Noncontrolling interest77
Stockholders’ deficit:

Item 1. Financial Statements

FAQ

What is Ultragenyx Pharmaceutical's liability related to sale of future royalties?
Ultragenyx Pharmaceutical (RARE) reported liability related to sale of future royalties of $1.13B in Q2 2026.
How has Ultragenyx Pharmaceutical's liability related to sale of future royalties changed year-over-year?
Ultragenyx Pharmaceutical's liability related to sale of future royalties increased by 43.9% year-over-year, from $782.75M to $1.13B.
What is the long-term trend for Ultragenyx Pharmaceutical's liability related to sale of future royalties?
Over 5 years (2020 to 2025), Ultragenyx Pharmaceutical's liability related to sale of future royalties has grown at a 27.9% compound annual growth rate (CAGR), from $335.67M to $1.15B.
What does liability related to sale of future royalties mean?
Liability Related To Sale Of Future Royalties as reported by Ultragenyx Pharmaceutical Inc..

Ask your AI about Ultragenyx Pharmaceutical's liability related to sale of future royalties.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude